Categories: News

MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MARIETTA, Ga., July 20, 2021 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the second quarter ended June 30, 2021 after the market close on Tuesday, August 3, 2021. MIMEDX management will host a webcast and conference call to review its results on Wednesday, August 4, 2021, beginning at 8:30 am Eastern Time.

The conference call can be accessed using the following information:

Webcast: https://edge.media-server.com/mmc/p/2gfy7rx3
U.S. Investors: 877-359-9508
International Investors: 224-357-2393
Conference ID: 8777681

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com

Staff

Recent Posts

Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE:…

1 hour ago

Don’t Let the Fear of Prep Stop You from Being Screened

Patients and experts highlight the importance of colorectal cancer screening and prevention CENTER VALLEY, Pa.,…

5 hours ago

Garrett and Rohde & Schwarz develop an integrated solution for high security screening applications

Garrett integrates its walk-through metal detector with the Rohde & Schwarz' R&S QPS201 security scanner. The…

5 hours ago

FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 2, 2025 /PRNewswire/…

5 hours ago

University Lab Partners Welcomes Groundbreaking MedTech Companies to the I-CREATE Accelerator Program

IRVINE, Calif., April 2, 2025 /PRNewswire/ -- University Lab Partners (ULP) proudly announces the selection…

5 hours ago

PrimeRx Pharmacy Ecosystem: Helping Independent Pharmacies Stay Ahead of the Curve and Accelerate Growth

UNIONDALE, N.Y., April 2, 2025 /PRNewswire/ -- PrimeRx, a trusted leader in pharmacy management solutions, is…

5 hours ago